Everything we track on one stock

RNA Atrium Therapeutics insider & Congress trades

Atrium Therapeutics, Inc.

InsidersPoliticiansBig moneyPunditsShort interestDividendEarnings

Insiders · 90d0no Form 4 insider trades filed in 90 days
Cluster buy🔒Whether several insiders bought together, for subscribers
Dividend safety—not in our dividend safety list
Last earningsQ3 2026reported Nov 12, 2026 · 1 release on file
Sentiment—no discussion summary yet
Politicians0no disclosed trades by members of Congress
Pundits0no calls from the pundits we track
Big money0 funds · 4 stakestracked hedge funds in their latest 13F · 13D/13G 5%+ filings
Short interest21.9% of shares short Squeeze risk3.75M shares short · +0.61% vs prior · 16.1 days to coverLow < 7%30%

🔒 Unlock everything on RNA

Subscribers see every insider trade, the dividend safety rating, pundit hit rates and watchlist alerts.

Subscribe$9.99/month, renews automatically each month until you cancel. Cancel anytime from your account page.
Popular tickers free to explore, every section unlocked
SEC Form 4

Insider trades

0 insider trades in the last 90 days.

🔒 Unlock every RNA trade →

No SEC Form 4 insider trades on file for RNA yet. We check EDGAR hourly.

House disclosures

Politician trades

No member of Congress has disclosed a RNA trade in our data yet.

13D/13G · 13F

Big money

4 13D/13G big-stake filings (5%+ owners) on file.

All big stakes →   13F moves →

5%+ owners

  1. 1
    T. Rowe Price Associates, Inc.13G passive
    Update · filed Nov 16, 2026
    3.7%was 8.6%
  2. Big-stake filing for subscribers
  3. Big-stake filing for subscribers
  4. Big-stake filing for subscribers
Pundit tracker

Who called RNA?

None of the pundits we track has made a call on RNA yet.

FINRA Rule 4560

Short interest

Open short positions in RNA as of the Oct 30, 2026 settlement.

FINRA source ↗
% of shares short21.9%Squeeze risk
Shares short3.75M
Change vs prior+0.61%+22.9K shares
Days to cover16.1
Avg daily volume233.3K
Prior period3.73M

Data: FINRA, as of Oct 30, 2026. Shares outstanding from SEC XBRL as of Aug 3, 2026. Short interest is a twice-monthly snapshot of open short positions reported by broker-dealers under FINRA Rule 4560. It is not a live figure. FINRA Equity Short Interest ↗

Dividend safety

Is the dividend safe?

RNA isn't in our dividend safety list (it may not pay a regular dividend).

8-K Item 2.02

Earnings releases

1 earnings release on file. Reported results only.

🔒 Unlock every report →
  1. 1
    Q3 2026filed Nov 12, 2026
    🔒 Headline figures and summary for subscribers.

Sources: SEC EDGAR (Form 4, 8-K, Schedule 13D/13G, 13F), FINRA consolidated equity short interest, House periodic transaction reports, public posts on X, and our price data for returns. We never show share prices. Not investment advice.

Look up another ticker